Coya Therapeutics (COYA, Financial) has reported encouraging interim findings from an exploratory study evaluating a combination treatment of low-dose IL-2 and CTLA4-Ig for patients with Frontotemporal Dementia (FTD). The ongoing study, designed to test this novel treatment approach, includes up to 10 participants, with the latest data encompassing five patients who have completed the 22-week treatment cycle.
The investigated treatment involved administering CTLA4-Ig subcutaneously, followed by a five-day regimen of low-dose IL-2 every four weeks. The initial findings suggest that this treatment was well-received, with the most frequent side effect being mild reactions at the injection site. Notably, there were no serious adverse events reported.
Biomarker analysis conducted prior to the study indicated that FTD patients generally show a weakened immunosuppressive function of regulatory T cells and elevated levels of inflammatory cytokines and chemokines. These factors point to the immune system's significant role in FTD's underlying mechanisms. Post-treatment assessments revealed a significant increase in both the quantity and function of regulatory T cells in participants.
Clinical assessments measuring cognitive function were performed using established scales, including the Clinical Dementia Rating – Frontotemporal Lobar Degeneration scale, the Montreal Cognitive Assessment scale, and the Progressive Aphasia Severity Scale. The results showed that, on average, the treated patients experienced minimal to no cognitive decline during the treatment period.
Coya Therapeutics plans to release further detailed data in future scholarly publications and conferences. This study's findings provide a positive outlook on the potential of low-dose IL-2 and CTLA4-Ig as a treatment avenue for FTD, promising new hope for those affected by this challenging condition.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 5 analysts, the average target price for Coya Therapeutics Inc (COYA, Financial) is $16.10 with a high estimate of $18.00 and a low estimate of $14.00. The average target implies an upside of 145.43% from the current price of $6.56. More detailed estimate data can be found on the Coya Therapeutics Inc (COYA) Forecast page.
Based on the consensus recommendation from 5 brokerage firms, Coya Therapeutics Inc's (COYA, Financial) average brokerage recommendation is currently 1.8, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
